Killian Donovan
@KillianDonovan
@Kidney_research doctoral research fellow studying CKD progression @Oxford_NDPH. Renal medicine and ICM specialty registrar.
Great examples underlining the importance of large, randomised trials in this review from @doreen_zhu @willkidney et al. Well worth a read!
If you haven’t heard why Oxford Renal Studies Grp believe innovations in conduct of trials r more important than developing surrogates & new analytic methods then this is your bedtime read 4 tonight!!! Not exhilarating, until you see the magic of examples. academic.oup.com/ndt/article/40…
Nephrology paradigm: Iron deficiency is relevant only to anemia Cardiology/haematology paradigm: Anemia is a late manifestation of iron deficiency, which itself has deleterious effect on skeletal & cardiac muscle energetics, independent of anemia nature.com/articles/s4159…
Systematic Review of the Effects of Iron on Cardiovascular, Kidney and Safety Outcomes in Patients With Chronic Kidney Disease Iron therapies may reduce the risk of heart failure or cardiovascular death in patients with CKD kireports.org/article/S2468-…
With universities unable to afford them, clinical academics across the country are being offered redundancy. These are the people who teach our doctors and conduct ground breaking research. More must be done to support them.
You’re covering a hospital and get called for a consult. You’re not the primary doctor. You open the chart to review imaging. All you need to do is look at one CT, Xray, or lab result—but the EHR won’t let you proceed without clicking through a series of unrelated alerts: ✔️…
376 on dialysis with placebo versus 296 with 10 mg of empa. That is a lot of misery avoided #KidneyWk
EMPA-KIDNEY post-trial f-up has revealed helpful findings on #SGLT2i in #CKD. We hope residual uncertainties r resolving & more pts r treated early & long-term. Deep gratitude to 1600+ collaborators & 6609 pts.#KidneyWk @NatalieStaplin @RichardHaynes3 @MartinLandray @Oxford_NDPH
Presented at #KidneyWk: Two years of empagliflozin slowed kidney disease progression or cardiovascular death. In a post-trial study, empagliflozin had additional cardiorenal benefits after discontinuation. Full post-trial study results: nej.md/3NE3W7K
Come visit poster 1000 and 1001 if you want to learn more about selection bias in GWAS of kidney disease progression or the relationship between adiposity, CKD and CVDs — thanks @Kidney_Research and @Oxford_NDPH !! #ASN24 #KidneyWeek2024 @grecombm @willkidney @KaitlinMayne
One of the common criticisms of NephroCheck and other biomarkers of AKI is that since we don't have a treatment for AKI, checking these do not change what we do. But I think this view isn't thoughtful. Given that most of the contrast associated nephropathy we see after cardiac…
Hypernatremia, intensivists vs nephrologists
🧵regarding the useful technique of 'straightening the wire' during central line placement when the plastic guide is no longer within reach. If you do a lot of central lines (or a lot of percutaneous procedures), this technique will come in handy over and over again. (1/ )
Here, @NEJM Case Records of @MGHMedicine got a little too aggressive, and in doing so showed their hand nejm.org/doi/full/10.10… The discussant, Dr. Edlow, predicts that the woman who presented with obvious subarachnoid hemorrhage and an elevated troponin, must have SAH *and*…
Listening to BellX1 for the first time in a long time this evening - I had completely forgotten how brilliant they are. "The Upswing" is such a moving song. Thank you for the music @BellX1 !
FLOW editorial by @willkidney & @RichardHaynes3 in @NEJM: “These data should be a stimulus for embarking on large renoprotection trials of GLP-1 RA for patients without diabetes, as well as for persons with diabetes & minimal or modest albuminuria” nejm.org/doi/full/10.10…
1/ Ever wonder: Why are abdominal aortic aneurysms (AAAs) more common than thoracic aortic aneurysms (TAAs)? I have! Follow this thread to see how the answer to this question makes use of long-forgotten medical classes. And there’ll be an appearance by The Great Mimicker.